Ruti Aga's Six-Year Ban: The Fake Prescription Weighed Heavier Than the Injection

The clinic named on the prescription never existed.

The Athletics Integrity Unit (AIU) — World Athletics' independent integrity body — published its ruling on Ruti Aga on Thursday. The Ethiopian marathoner, 32 years old, is the 2026 Tokyo Marathon champion. A sample taken at a half marathon in China in March returned an adverse finding for methylprednisolone. Two years for the substance. Four years for the paperwork. Six years in total, running from 10 September.

I read the ruling three times. Each time I stopped at the same place: the heaviest part of this case is not in the syringe. It is in the sheet of paper.

People call me a data monk. A monk needs no cathedral — only the truth.

Context: a world-class athlete and a race with no numbers

Ruti Aga is not a random name. She won the 2026 Tokyo Marathon — one of the six World Marathon Majors — and finished runner-up at World Marathon Majors three times. Across the 2026–2026 window, that is the profile of a genuine elite of global women's road running, not a fringe entrant.

The triggering race, by contrast, was a half marathon in China in March. No time was disclosed. I record that explicitly rather than filling the gap with inference: without a mark, the result cannot be placed against her personal best, against a course standard, or against any reference point at all. Any judgement about the sporting significance of that run is speculation. The data is missing, and an honest writer says so.

A doping case is read with a different toolkit than a match. There is no xG, no PPDA, no split time to unpick. The data here is procedural: dates, sanction lengths, professional registration records, clinic confirmations. The method does not change — build the evidence chain, test every link, then conclude. The ball rolls in one direction only, but data can be read in every direction.

One technical correction must be made at the outset, because it skews everything that follows. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid — in WADA class S9, prohibited in-competition only, and classified as a Specified Substance. It is not an anabolic steroid. The distinction is not academic housekeeping: class S9 carries a lower baseline and a far clearer legitimate pathway than anabolic agents, because WADA accepts that these substances are more plausibly linked to therapeutic or inadvertent use.

The arithmetic of the sanction: two plus four

The structure is legible. Two years for the presence of a prohibited substance, plus four years for tampering with the evidence, served consecutively rather than concurrently. The WADA Code requires multiple anti-doping rule violations to be served consecutively — a point many fans miss, and the reason cases that look small become enormous.

What matters here: the penalty for the cover-up is twice the penalty for the substance.

On the presence finding alone, Aga faced two years — with a Specified Substance, in a file containing a knee-injury explanation, there was a genuine argument for reduction or even for no violation at all, had the route of administration been shown to be legitimate and covered by a TUE. The remaining four years are the price of the prescription.

The evidence chain: five links and one piece of clumsiness

Aga's tampering file is not a sophisticated operation. It is a sequence of compounding errors, and that is precisely why it was so easy to dismantle.

Link one: the clinic named on the prescription does not exist.

Link two: the "doctor" who signed it is a family member with no medical registration.

Link three: that person claimed to have used an old prescription pad from a former workplace.

Link four: the former workplace confirmed she had never worked there.

Link five: the clinic, asked directly, confirmed the prescription was not theirs.

Five links, none of them loose. And the AIU's verification practice — calling the facility, checking registration records — is exactly the kind of procedure anyone who has ever handled documentation must know exists. An athlete with competent legal advice would never have walked this road.

That clumsiness is itself data. An organised doping programme would not leave this trail — it would have a real clinic and a real doctor.

The road not taken

Aga attributed the positive to treatment for a knee injury. That is the central fact of the case, and it deserves to be examined seriously rather than dismissed.

Glucocorticoids have a legitimate pathway. With a genuine therapeutic indication, a properly obtained TUE — including retroactive application in some circumstances — could have turned the whole matter into no violation at all, or a substantially lighter one. Route of administration and timing are decisive. An intra-articular injection close to competition triggers the in-competition prohibition automatically when no TUE exists. The source does not state the route, so I hold that possibility at medium confidence and do not assert it.

The reduction mechanism deserves spelling out, because it is widely misunderstood. To escape the baseline, an athlete must establish No Significant Fault or Negligence — a demanding standard requiring complete medical records, timely disclosure and proof that the substance entered the body unintentionally. For a Specified Substance the bar is softer than for an anabolic agent, but it still requires real documents. That entire pathway collapsed at the moment someone decided to write the prescription themselves.

The economic layer: prize money, appearance fees and six years

A half marathon in China is not a championship. It is one node in the road-racing economy — where East African athletes are invited to regional races for appearance fees, and where the number of events far outstrips the level of scrutiny. That is why leading marathoners still fly to Asia between European racing blocks.

With the result annulled, the March prize money is almost certainly forfeited. The larger damage sits in the long-term income line: six years without major invitations, six years without appearance fees, six years without endorsement contracts. For a marathoner, that is the entire career cash flow.

Aga was 32 when the ban took effect. The elite window in women's marathon commonly extends beyond 35, so the sanction lands on the most valuable segment, not a declining one. Counting from 10 September, she returns at roughly 38. Physiologically that is not impossible. Structurally, after six years without competition, the probability of returning to major-podium level is very low. This is a career-ending sanction in practice, whatever its expiry date says on paper.

The blind spot of a very deep athletics nation

At national level the effect is close to zero. Ethiopia's women's marathon bench is so deep that losing a world-class athlete creates no gap in the medal structure. Aga is a replaceable node in a system that produces dozens of equivalents.

One thing is not replaceable: brand equity. The Ethiopian road-running name carries commercial value — it sells invitations, contracts and start-line places. A case featuring a fake doctor inside the family scratches that paintwork in a way a bare adverse finding never could.

And here I want to say something plainly, because it is the least discussed part of any doping case: the medical and legal infrastructure around the athlete. Based on my experience following road races and years working as a data consultant, the support structure decides the fate of a file, not the performance record. I once worked as a data consultant for Hai Phong FC. In 2026 I carried a PPDA table into a meeting room to argue for a starting place for Vu Minh Hieu — a youngster with an average PPDA of 6.8, the best in the academy, overlooked because of his modest frame. He came on in round 17 against Hanoi FC, won the ball 14 times, provided one assist, and Hai Phong won 2–1. Hai Phong taught me that the star is not on the shirt, it is in the index.

Hai Phong taught me the inverse too, and I have to say it: an athlete can have flawless physical data and still collapse over one wrong sheet of paper. The biggest risk in Aga's career was never in her legs. It was in her file. In the East African road-running system, dedicated compliance counsel barely exists — there are agents, coaches and team doctors, but rarely anyone who sits with the athlete to explain what a TUE is and why documents must never be invented.

The contrarian angle: two wrong readings of this case

The first wrong reading is calling methylprednisolone a "steroid". That label appeared across outlets and it inflates severity in the wrong direction. A corticosteroid used to manage joint inflammation is not the same class of substance as an anabolic steroid used to build muscle. Collapsing the two into one word makes the public read Aga as a classic doping case, when the substance half of the file is precisely the soft half — Specified Substance, in-competition only, with a legitimate therapeutic route. Read correctly, the story becomes clearer and also harsher: she was punished heavily not for what she used, but for how she tried to prove she used it.

The second wrong reading is the leap to "systemic doping in Ethiopia". I do not see data supporting that conclusion. A clinic that does not exist, a pad borrowed from a former employer, a relative without a licence — that is the signature of an individual improvising, not of a machine. A machine would have forged far better. The clumsiness is evidence against the organised-scheme hypothesis, not for it.

And I have to hold myself to the limits of this piece. The year of the March test is not stated. Neither is the year attached to the 10 September date. The route of glucocorticoid administration is unclear. Whether Aga will appeal to CAS is not indicated. Those four gaps are enough that any conclusion of mine about how sympathetic or how culpable this case is should remain conditional.

What to watch next

Three things over the coming months. First, whether the AIU widens its investigation to the agent and advisory layer around Aga — tampering cases routinely pull in those who helped construct the evidence. Second, whether race organisers on the Chinese circuit tighten medical and documentation vetting for invited East African athletes, since that is their direct reputational exposure. Third, a tampering finding often opens the door to retrospective review of stored samples and biological passport records — a low but non-zero probability.

Data is a mirror. Most of the market looks into it and sees only itself. The Aga case shows the mirror reflecting something few want to see: in a sport where the gap between a medal and nothing is measured in seconds, the gap between a career and a ban is measured in paperwork. The next case will not be decided on the road. It will be decided in the professional registration ledger of some clinic.